(NGVT) Ingevity - Overview
Stock: Activated Carbon, Specialty Polymers, Caprolactone, Road Additives, Emission
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 46.1% |
| Relative Tail Risk | -11.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.17 |
| Alpha | 42.81 |
| Character TTM | |
|---|---|
| Beta | 1.386 |
| Beta Downside | 1.672 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.07% |
| CAGR/Max DD | -0.09 |
Description: NGVT Ingevity January 16, 2026
Ingevity Corp. (NYSE:NGVT) manufactures activated carbon products, specialty chemicals, and engineered polymers for a global customer base spanning North America, Asia-Pacific, Europe, the Middle East, Africa, and South America. The firm operates through three segments: Performance Materials (hardwood-based and chemically activated carbon for vapor emission control and purification), Performance Chemicals (road-construction additives, agro-chemical dispersants, lubricants, and related industrial specialties), and Advanced Polymer Technologies (caprolactone-based polymers for coatings, elastomers, bioplastics, and medical devices).
Key sector drivers include tightening global emissions standards that sustain demand for gasoline vapor recovery carbon, and the growing market for biodegradable plastics that underpins caprolactone sales. Ingevity’s FY2023 revenue was approximately $1.1 billion, with an adjusted EBITDA margin of roughly 12%, reflecting modest profitability amid competitive pressure.
Recent trends suggest a potential headwind from the accelerating shift to electric vehicles, which could reduce gasoline-related carbon demand, while the company’s diversification into road-preservation chemicals and biopolymer applications offers a partial hedge. The activated carbon market’s base-rate growth is estimated at 5-6% CAGR through 2028, driven largely by regulatory mandates in the United States and the European Union.
For a deeper dive into NGVT’s valuation metrics, you might explore the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 124.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 14.64 > 1.0 |
| NWC/Revenue: 8.86% < 20% (prev 18.66%; Δ -9.80% < -1%) |
| CFO/TA 0.19 > 3% & CFO 349.3m > Net Income 124.1m |
| Net Debt (1.18b) to EBITDA (238.2m): 4.94 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.0m) vs 12m ago -0.82% < -2% |
| Gross Margin: 38.68% > 18% (prev 0.28%; Δ 3840 % > 0.5%) |
| Asset Turnover: 61.75% > 50% (prev 66.89%; Δ -5.14% > 0%) |
| Interest Coverage Ratio: 1.93 > 6 (EBITDA TTM 238.2m / Interest Expense TTM 84.3m) |
Altman Z'' 2.11
| A: 0.06 (Total Current Assets 522.2m - Total Current Liabilities 411.6m) / Total Assets 1.83b |
| B: 0.27 (Retained Earnings 489.5m / Total Assets 1.83b) |
| C: 0.08 (EBIT TTM 162.5m / Avg Total Assets 2.02b) |
| D: 0.29 (Book Value of Equity 489.5m / Total Liabilities 1.70b) |
| Altman-Z'' Score: 2.11 = BBB |
Beneish M -3.52
| DSRI: 1.05 (Receivables 168.1m/189.9m, Revenue 1.25b/1.48b) |
| GMI: 0.72 (GM 38.68% / 27.87%) |
| AQI: 0.93 (AQ_t 0.36 / AQ_t-1 0.38) |
| SGI: 0.84 (Revenue 1.25b / 1.48b) |
| TATA: -0.12 (NI 124.1m - CFO 349.3m) / TA 1.83b) |
| Beneish M-Score: -3.52 (Cap -4..+1) = AAA |
What is the price of NGVT shares?
Over the past week, the price has changed by +10.49%, over one month by +15.62%, over three months by +57.34% and over the past year by +66.07%.
Is NGVT a buy, sell or hold?
- StrongBuy: 1
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NGVT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 70.8 | -2.7% |
| Analysts Target Price | 70.8 | -2.7% |
| ValueRay Target Price | 86.4 | 18.8% |
NGVT Fundamental Data Overview February 03, 2026
P/S = 1.7358
P/B = 17.1669
P/EG = 2.05
Revenue TTM = 1.25b USD
EBIT TTM = 162.5m USD
EBITDA TTM = 238.2m USD
Long Term Debt = 1.16b USD (from longTermDebt, last quarter)
Short Term Debt = 102.0m USD (from shortLongTermDebt, last quarter)
Debt = 1.45b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 1.18b USD (from netDebt column, last quarter)
Enterprise Value = 3.77b USD (2.40b + Debt 1.45b - CCE 83.4m)
Interest Coverage Ratio = 1.93 (Ebit TTM 162.5m / Interest Expense TTM 84.3m)
EV/FCF = 12.97x (Enterprise Value 3.77b / FCF TTM 290.6m)
FCF Yield = 7.71% (FCF TTM 290.6m / Enterprise Value 3.77b)
FCF Margin = 23.27% (FCF TTM 290.6m / Revenue TTM 1.25b)
Net Margin = 9.94% (Net Income TTM 124.1m / Revenue TTM 1.25b)
Gross Margin = 38.68% ((Revenue TTM 1.25b - Cost of Revenue TTM 765.9m) / Revenue TTM)
Gross Margin QoQ = 40.20% (prev 40.20%)
Tobins Q-Ratio = 2.06 (Enterprise Value 3.77b / Total Assets 1.83b)
Interest Expense / Debt = 1.35% (Interest Expense 19.6m / Debt 1.45b)
Taxrate = 34.41% (21.4m / 62.2m)
NOPAT = 106.6m (EBIT 162.5m * (1 - 34.41%))
Current Ratio = 1.27 (Total Current Assets 522.2m / Total Current Liabilities 411.6m)
Debt / Equity = 10.53 (Debt 1.45b / totalStockholderEquity, last quarter 138.1m)
Debt / EBITDA = 4.94 (Net Debt 1.18b / EBITDA 238.2m)
Debt / FCF = 4.05 (Net Debt 1.18b / FCF TTM 290.6m)
Total Stockholder Equity = 176.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.14% (Net Income 124.1m / Total Assets 1.83b)
RoE = 70.31% (Net Income TTM 124.1m / Total Stockholder Equity 176.5m)
RoCE = 12.17% (EBIT 162.5m / Capital Employed (Equity 176.5m + L.T.Debt 1.16b))
RoIC = 7.02% (NOPAT 106.6m / Invested Capital 1.52b)
WACC = 7.19% (E(2.40b)/V(3.85b) * Re(11.02%) + D(1.45b)/V(3.85b) * Rd(1.35%) * (1-Tc(0.34)))
Discount Rate = 11.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.21%
[DCF Debug] Terminal Value 77.56% ; FCFF base≈185.1m ; Y1≈145.9m ; Y5≈96.0m
Fair Price DCF = 25.55 (EV 2.10b - Net Debt 1.18b = Equity 919.1m / Shares 36.0m; r=7.19% [WACC]; 5y FCF grow -25.26% → 2.90% )
EPS Correlation: -44.03 | EPS CAGR: -52.09% | SUE: -2.74 | # QB: 0
Revenue Correlation: -54.76 | Revenue CAGR: -0.24% | SUE: -1.71 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.82 | Chg30d=-0.083 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=4.47 | Chg30d=-0.546 | Revisions Net=+0 | Growth EPS=+0.4% | Growth Revenue=-5.2%